NCT00080899View on ClinicalTrials.gov

Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions
Adenocarcinoma of the ProstateRecurrent Prostate Cancer
Interventions
DRUG

fenretinide

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

90033

University of Southern California, Norris, Los Angeles

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00080899 - Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer | Biotech Hunter | Biotech Hunter